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ABSTRACT
Amonafide is a new imide derivative of naphthalic acid.
The drug had demonstrated significant activity in preclini-
cal studies and some activity in Phase I trials. The drug is
extensively metabolized and detected in plasma and urine.
Its toxicity has previously been correlated to the formation
of an active metabolite, N-acetyl-amonafide. Amonafide was
chosen for inclusion in the Cancer and Leukemia Group B
(CALGB) master metastatic breast cancer protocol.
CALGB 8642 randomizes previously untreated metastatic
breast cancer patients either to one of several Phase II
agents given for up to four cycles and then followed by
standard cyclophosphamide-doxorubicin-5-fluorouracil, or
to immediate treatment with standard cyclophosphamide-
doxorubicin-5-fluorouracil. The end point of CALGB 8642
is to assess the difference in survival, toxicity, and overall
response when limited exposure to Phase II agents precedes
standard chemotherapy. This report deals only with
amonafide as a Phase II agent. Comparisons with the cyclo-
phosphamide-doxorubicin-5-fluorouracil arm will not be
addressed. Patients had to have histologically documented
measurable breast cancer and a performance status of 0-1.
Patients could not have had prior chemotherapy for meta-
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static disease. Prior adjuvant chemotherapy was permitted.
Patients could not have visceral crisis. Amonafide was given
at 300 mg/m2/day i.v. for 5 days, and repeated at 21-day
intervals for a maximum of four cycles. Escalation and
reduction in dose was mandated dependent on hematotox-
icity or lack thereof. Toxicity was primarily hematological
and bimodal: 32% had grade 3 or 4 leukopema and 24%
had grade 3 or 4 thrombocytopenia; 22% had no leukopenia
and 44% had no thrombocytopenia. The response rate was
18%, including one complete response. When response was
analyzed by hematological toxicity, there was a 35.7% re-
sponse if patients had leukopenia grade 3/4 (versus 8.3%, P
= 0.08). There was a 50% response if patients had throm-
bocytopenia grade 3/4 (versus 7.1 %, P = <0.01). We con-
dude that amonafide is somewhat active in previously un-
treated breast cancer patients. There may be a steep dose-
response curve, based on the significant correlation between
myelosuppression and response. Rates of responses in pa-
tients adequately dosed (i.e., with significant hematotoxicity)
with amonafide ranged from 35 to 50%. Further studies will
incorporate individualized dosing based on pretreatment
acetylator phenotyping.
INTRODUCTION
Traditionally the use of Phase II agents in breast cancer
patients has been limited to heavily pretreated patients. The
performance of active Phase II agents will almost certainly be
inferior to that which might have been observed in previously
untreated patients. The most striking example of this is the poor
response rate of doxorubicin (Adriamycin) when used as a
Phase II agent in the traditional setting (1). Since there is
widespread acknowledgment of the pressing need to discover
new and active agents for this disease, some centers are begin-
ning to use Phase II agents in previously untreated breast cancer
patients, although this practice has not been demonstrated to be
safe to the patient (2, 3). In order to address the safety as well
as the benefit of using Phase II agents in previously untreated
patients, the CALGB3 has developed a master protocol (CALGB
8642) that compares survival, toxicity, and cumulative response
rate in previously untreated patients randomized either to Phase II
agents for up to four cycles followed by standard CAF regimen or
to the CAF arm alone. Five single agents will be tested sequentially
before the trial closes (4, 5). This is a report of the Phase II
evaluation of amonafide as a part of protocol 8642.
3 The abbreviations used are: CALGB, Cancer and Leukemia Group B;
CAF, cyclophosphamide-doxorubicin-5-fluorouracil; UTSA, University
of Texas at San Antonio; OSU, Ohio State University; MDA, M. D.
Anderson; MTh, maximum tolerated dose.
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Preclinical Studies. Amonafide (benzisoquinolinedione,
BIDA, NSC308847) is a new imide derivative of naphthalic acid
(6). When the naphthalic acid side chain has two methylene
groups with a terminal nitrogen, as amonafide has, cytotoxic
activity is maximum. Amonafide has demonstrated significant
activity against P388 leukemia and L1210 cell lines as well as
B16 melanoma and M5076 sarcoma cell lines (7). Amonafide is
a site-specific intercalating agent and a topoisomerase II in-
hibitor (8, 9). Preliminary human pharmacology shows that
amonafide is extensively metabolized, and the metabolites have
been detected in both plasma and urine. The principal metabo-
lite, N-acetyl-amonafide is cytotoxic (10).
Phase I Studies. Phase I studies were performed at the
UTSA (1 1), OSU (12), and MDA (13). When given as a single
bolus, the MTD was 800 mg/rn2. The dose-limiting toxicity was
myelosuppression (UTSA). When a daily times five dose was
given every 21 days, the MTh was 400 mg/rn2 (MDA) or 250
mg/rn2 (OSU). Again, myelosuppression was the dose-limiting
toxicity. Other reported toxicities were mild to moderate nausea,
vomiting, and alopecia. All three centers reported acute toxicity
with rapid amonafide infusion. This consisted of local inflam-
matory reactions, diaphoresis, flushing, tinnitus, headache,
and/or dizziness. Increasing the duration of the infusion to 1 h
minimized these effects. One complete response was noted at
UTSA in lung cancer.
Regarding the different regimens, no schedule dependency
was noted. The bolus dose MTD was different in two studies.
The UTSA investigators (1 1) showed a highly variable and
individualized hematotoxicity at sub-MTD doses, although they
did reach a MTD of 800 mg/m2. The OSU study (12) reported
an MTD of 1125 mg/rn2 but noted considerable and variable
toxicity.
One group (12) compared bolus doses (1125 mg/rn2) to a
5-day schedule (at 288 mg/rn2) and concluded that the 5-day
schedule was preferred since more drug could be given. In
another 5-day schedule, the MDA study (13) found a higher
MTD of 400 mg/rn2.
We chose to use the 5-day schedule so that more drug could
be given. We chose to begin with 300 mg/rn2 as a compromise
between the recommended start dose of 220 mg/rn2 (12) and
400 mg/rn2 (13). Because of the variability in dose-limiting herna-
totoxicity seen in the three Phase I trials, an escalation dose of
100 mg/rn2/cycle was mandated. Because arnonafide demonstrated
significant activity in tumor cell lines and because it was a new
agent of interest, it was chosen for testing in CALGB 8642, the
metastatic breast cancer master protocol.
Phase II Studies. Subsequent to our initiation of this
trial, a report (14) was published indicating that amonafide had
activity in rnetatastic breast cancer. In that study, a single 3-h
infusion dose of 800 mg/rn2 every 28 days was used. Three
responses were noted in eight patients who had not received
prior chemotherapy.
PATIENTS AND METHODS
Eligibility Criteria. Eligible patients had to have histo-
logically documented measurable breast carcinoma (either stage
IV or inoperable disease), performance status of 0-1 (Eastern
Cooperative Oncology Group scale), life expectancy of greater
than 4 months, age greater than 16 years and physiological age
of less than 70, and adequate function of bone marrow, kidney,
and liver. Patients could not have had prior chemotherapy treat-
ment for metastatic disease. Adjuvant chemotherapy for breast
cancer was permitted if more than 12 months had intervened
since the completion of therapy. Doxorubicin could have been
used as an adjuvant agent but the cumulative dose could not
exceed 250 mg/rn2. Hormone therapy was permissible but 4
weeks had to intervene between cessation and entry on this
protocol. In addition, patients could not have had visceral crisis,
defined as lymphangitic spread of the disease to lungs, bone
marrow replacement, carcinornatous meningitis, or significant
liver disease. All patients were required to sign an informed
consent document.
Treatment and Dose Modifications. Amonafide was
supplied by the Division of Cancer Treatment at the National
Cancer Institute as a lyophilized powder. The drug was recon-
stituted in 4 ml sterile water of 0.9% sodium chloride with a
concentration of 26 rng/ml with a pH of 5-7. After reconstitu-
tion and dilution, arnonafide was infused over 1 h through an
established free-flowing i.v. line. The schedule of drug adrnin-
istration was 300 rng/m2/day iv. for 5 days, repeated at 21-day
intervals. Escalation was required for Day 15 granulocytes of
1,000 or greater and platelet count of 75,000 or greater. The
daily dose of amonafide was to be increased by 100 mg/rn2/day/
cycle. Doses were reduced by 50% if on the day of treatment
(Day 1), granulocyte and platelet counts were below 1,800 or
100,000 respectively. No therapy was given if Day 1 granulo-
cytes and platelet counts were below 1,000 and 75,000. After
two cycles of amonafide, response was to be evaluated. If
progressive disease was noted, patients did not receive more
arnonafide and began standard CAF therapy. Patients were to
begin standard CAF therapy after a maximum of four cycles of
amonafide, even if responding to amonafide.
Pretreatment Evaluation. Pretreatment evaluation in-
eluded complete history and physical examination including
blood pressure, pulse, height, weight, surface area, performance
status, tumor measurements, laboratory tests consisting of WBC
count, platelet count, differential, blood urea nitrogen, creati-
nine, creatinine clearance, electrolytes, calcium, serum transarn-
inase, alkaline phosphatase, bilirubin, uric acid, phosphate, glu-
cose, total protein, albumin, urine analysis, electrocardiogram,
chest X-ray, and bone scan. A liver scan was required only if
enlarged liver or abnormal liver function studies were docu-
mented. Computerized tomography of the abdomen and liver,
bone marrow aspiration, and biopsy were not required unless
they were clinically appropriate. Disease was categorized by the
site of metastases: viscera, bones, or soft tissue. Evaluation
during treatment included a complete history and physical ex-
amination, tumor measurement, WBC count and platelets, blood
chemistries, and urinalysis on Day 1 of each of the cycles.
Weekly WBC count, differential, and platelet count were also
required. Formal evaluation of drug toxicity was to be done on
Day 1 of each cycle.
Criteria for Evaluation. Patients were stratified by es-
trogen receptor protein status, dominant site of metastatic dis-
ease, and menopausal status. The definitions of response were:
complete response was defined as the disappearance of signs
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and symptoms related to measurable disease without the appear-
ance of new lesions for a period of at least 4 weeks. Lytic lesions
had to recalcify to be scored as a complete response. Partial
response was defined as a reduction of 50% or greater in the
sum of the products of the perpendicular diameters of all mea-
surable lesions without the appearance of new lesions or an
increase in the size of existing lesions for 4 or more weeks.
Stable disease was defined as <50% reduction or <25% in-
crease in the sum of the products of the two perpendicular
diameters of all measured lesions without the appearance of new
lesions for a period greater than 8 weeks. Progressive disease
was defined as an increase in the product of two perpendicular
diameters of any measured lesion by 25% or more of the size
present at entry on study or for patients who responded to
therapy, or the appearance of new areas of malignant disease.
The toxicity criteria used were those of the National Cancer
Institute.
Pharmacological Studies. An optional companion phar-
macological study was conducted in conjunction with this and
other Phase II trials of arnonafide. The complete results were
reported separately (15). Plasma concentrations of amonafide and
its active rnetabolite N-acetyl-amonafide were determined by
HPLC analysis as described previously (16, 17). Slow acetylators
were defined as having 24-h N-acetyl-amonafide concentrations of
<80 ng/ml and fast acetylators had >100 ng/ml (13, 17).
RESULTS
Between April 1988 and February 1990, 52 patients were
randomized to the amona.fide arm. Six patients were ineligible. Of
the remaining 46 patients, 7 were inevaluable for response although
they were evaluable for toxicity. Of the seven inevaluable patients,
one died from breast cancer within 10 days of entering the study,
one patient withdrew consent, two patients refused further therapy
after one cycle, and three patients were on treatment less than two
full cycles of treatment due to excessive toxicity. Table 1 gives the
characteristics at entry for the 46 eligible patients. The majority of
patients were postmenopausal. Thirty-seven percent were estrogen
receptor negative. The dominant site of disease was visceral in 78%
of the cases. Thirty-nine percent of patients had received adjuvant
chemotherapy.
Toxicity
Hematological Toxicity. Twenty-four percent of pa-
tients had severe (grade 3) leukopenia and 9% experienced
life-threatening (grade 4) toxicity. Eleven percent of patients
had severe (grade 3) thrombocytopenia and 13% experienced
life-threatening (grade 4) thrombocytopenia (Table 2).
Gastrointestinal Toxicity. Grade 3 nausea and vomiting
was noted in 16% of patients and 4% had life-threatening nausea
and vomiting (Table 2).
Other Toxicity. Of the nonhernatological and nongas-
trointestinal toxic effects, the most common and troublesome
one was local toxicity consisting of phlebitis and/or local swell-
ing with erythema. Systemic allergic reactions occurred in seven
patients and consisted of one or more of the following: fever to
> 103#{176}F,rash, hives, and/or burning sensation of the scalp. One
patient developed the Stevens-Johnson syndrome. None of the
Table 1 Patient characteristics
No. of patients
Age (yr) (n = 46)
<40 3(7%)
40-49 10(22%)
50-59 20 (44%)
60-69 12 (26%)
70 1 (2%)
Performance status
0 30 (65%)
1 16 (35%)
Menopausal status
Premenopausal 7 (15%)
Peri/postmenopause 28 (61%)
Surgical menopause 11 (24%)
Estrogen receptor status
Positive 19 (41%)
Negative 17 (37%)
Unknown 7(15%)
Borderline 3 (7%)
Site of metastasis
Soft tissue” 27 (59%)
Visceral” 36 (78%)
Bone 22 (48%)
Principal prior therapies
Hormonal therapies 19 (41%)
Adjuvant chemotherapy 18 (39%)
Radiotherapy 15 (33%)
a Includes recurrent primary, inoperable primary chest wall, nodes,
and skin.
b Includes lung, pleura, liver, brain, and bone marrow.
patients received a rapid infusion of drug. Most of the systemic
allergic reactions occurred during the second cycle of drug
administration (Table 2).
Dose Modifications
One hundred thirteen courses of amonafide were given to
39 patients (average, 3.0 courses). Dose escalations were carried
out in 30% of the courses, and dose reductions were imple-
mented in 30% (see Table 3).
Responses
Responses are shown in Table 4. The complete remission
rate was 2.2% and the partial remission rate was 15.4%. The
overall response rate was 17.6%. Of the seven responders, three
patients had adjuvant chemotherapy. Four responders had re-
ceived prior endocrine therapy.
Duration of Response. Duration of response is not evalu-
able in this study since at the end of four cycles, all patients,
whether responding or not, began standard CAF therapy. Of the
seven responding patients, all were still responding at the time of
initiation of standard CAF therapy.
Response Rate and Hematopoietic Toxicity. Table 5
shows the relationship between significant granulocytic and/or
platelet toxicity and response status. Those patients who expe-
rienced grade 3 or 4 toxicity for either granulocytes or platelets
had a greater response rate than those who did not. The rela-
tionship was significant with respect to platelet toxicity.
Response Rate and Acetylation Status. Of the 18 pa-
tients who had plasma drug and rnetabolite concentrations de-
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Table 2 Pati ent toxicity
Maximum toxicity (n = 46)
0 (none) 1 (mild) 2 (moderate) 3 (severe) 4 (life-threatening)
Hematopoietic
Leukopenia 10 (22%) 10 (22%) 10 (22%) 11 (24%) 4(9%)
Thrombocytopenia 20 (44%) 10 (22%) 4 (9%) 5 (11%) 6 (13%)
Anemia 22 (49%) 7 (16%) 13 (29%) 2 (4%) 1 (2%)
Nonhematopoietic
Nausea and vomiting 15 (33%) 10 (22%) 11 (24%) 7 (16%) 2 (4%)
Hepatic 41 (93%) 1 (2%) 2 (5%) 0 (0%) 0(0%)
Renal 42 (93%) 2 (4%) 1 (2%) 0 (0%) 0 (0%)
Infection 37 (82%) 2 (4%) 2 (4%) 3 (7%) 1 (2%)
Local toxicity 28 (62%) 7 (16%) 5 (11%) 4 (9%) 1 (2%)
Systemic allergic reaction 39 (85%) 2 (4%) 3 (7%) 1 (2%) 1 (2%)
Table 3 Dose modifications
Dose
change Cycle 1 - 2 Cycle 2 - 3 Cycle 3 -* 4
Escalation I 1 7 5 23 (29.9%)
Reduction 15 4 4 23 (29.9%)
None 13 8 10 31 (40.3%)(same dose)
39 19 19 77
Table 4 Response rate (n 39)
Complete response 1 (2.2%)
Partial response 6 (15.4%)
Stable disease 16 (41%)
Progressive 16 (41%)
termined, 4 could not be evaluated for response and 4 could not
be evaluated for acetylation status. There were 10 patients
evaluable by acetylator status and by response. By acetylator
status, the response rates were 17% (1/6) in the slow group and
25% (1/4) in the fast group.
Response Rate and Prior Adjuvant Chemotherapy.
Of the 39 patients evaluable for response, 6 had prior adjuvant
doxorubicin. No response in these patients was noted. Of the 33
patients who had not received adjuvant doxorubicin, 10 received
other adjuvant chemotherapy. Response rate in these 10 patients
was 30%. These results are not significant because the numbers
are small.
Response Rate and Systemic Allergic Reactions. Of
the 39 patients evaluable for response, 30 did not receive ste-
roids as part of their antiemetic regimen and were thus ‘ ‘unpro-
tected’ ‘ for allergic reactions. Three of 4 patients having signif-
icant allergic reactions had a response, whereas only 1 of 26
patients without an allergic reaction had a response (P < 0.01).
Three additional patients who had systemic allergic reactions
could not be evaluated for response. The reactions included
hives, burning and darkened face, and rashes of grade 2-4
intensity. These occurred typically on the second or third day of
the second cycle.
TabI e 5 Response by hematopoietic toxicity
Total no. of
patients Response Response
(n 38)” Complete Partial rate
WBC
Grade 0, 1, 2 24 1 1 8.3%
Grade 3, 4 14 0 5 35.7%
p = 0.08
Platelets
Grade 0, 1, 2 28 1 1 7.1%
Grade 3, 4 10 0 5 50%
p < 0.01
a Of 39 patients evaluable for response, 1 had no nadir counts
available for review.
DISCUSSION
Amonafide, a new imide derivative of naphthalic acid, shows
minimal activity in breast cancer patients previously treated for
metastatic disease. Phase I studies did not indicate major activity,
although a single objective response (complete response) was noted
in a patient with adenocarcinoma ofthe lung (UTSA). In one Phase
II trial (14), objective responses were noted using a dose of 800
mg/rn2 every 4 weeks. Most patients in that study were considered
refractory to prior treatment, and 20 of 28 had prior chemotherapy
for their metastatic disease. In the 20 patients receiving prior
chemotherapy, there were only 2 responses (10%). However, three
responses were noted in the eight patients who had not received
prior chemotherapy for metastatic disease.
Our Phase II study is of interest because all evaluable
patients were previously untreated for metastatic breast cancer.
In general, breast cancer patients without prior exposure to
chemotherapy have a higher response to drug than patients with
previous treatment. However, in our study this was not the case.
The overall response rate in our study was 17.6%.
In this study we noted a negative relationship between
adjuvant doxorubicin chemotherapy and response to arnonafide.
While this was not a significant result (due perhaps to small
numbers), it is consistent with the observation that others have
made (14). Possible mechanisms for cross-resistance might in-
elude p-glycoprotein-associated drug-resistance phenomenon
(18). This resistance is inducible by Vinca alkaloids, anthracy-
dines, and podophyllotoxins derivatives. It is characterized by
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the decreased intracellular accumulation of cytotoxic drugs.
Another pathway might be the alteration of topoisomerases as is
the case with anthracyclines and epipodophyllotoxins (19).
These agents interfere with religation and stabilize the strand
passage reaction by causing mutations in DNA topoisomerases.
Again, prior exposure to doxorubicin may have resulted in
topoismerase II mutation.
An unexpected but significant finding was the association
of amonafide response and the experience of systemic allergic
reactions. A possible explanation of this association is that a
drug-induced immune reaction somehow interacted with breast
cancer cells, leading to their destruction. The result although
technically significant may be spurious since the numbers of
patients involved are small, and the observation is retrospective.
On the other hand, the association was remarkable in several
cases, prompting the retrospective analysis. The exact nature of
the allergic reactions themselves is unclear. The drug was given
slowly over at least 1 h. There was no sign of anaphylaxis,
arthritis, glomerulonephritis serum, or vasculitis sickness. Al-
lergic reactions consisted of hives, rashes, burning skin, fever to
103#{176}C,and/or the Stevens-Johnson syndrome. Whatever the
allergic responses induced by drug might be, it is less clear how
such responses might trigger cancer cell cytoxicity. Possible
pathways might include antibody-dependent cell cytotoxicity:
where drug and cancer cell share similar antigens (as in the
penicillin involved hemolysis of RBCs), or where drug and
antibody are passively absorbed onto a cancer cell, leading to
complement-activated cytotoxicity (as in Sedormid-induced
thrombocytopenia). Nonantibody pathways might include lym-
phocyte cell-mediated immune responses (as in natural killer-
type-mediated cancer cell cytotoxicity). Natural killer activity
might be triggered by cytokine release secondary to mast cell
release of histamines (20).
Nonetheless, given the association of cancer responses with
other immune-mediated reactions (21-23), this report of a pos-
sible association of allergic immune reactions and breast cancer
response is worth pursuing in prospective studies.
The most important finding in our study is the relationship
between myelosuppression, especially thrombocytopenia, and
response. It has been previously demonstrated that the major
determinant of myelosuppression is the genetically determined
acetylator phenotype (15, 17, 24). Unfortunately, only two re-
sponding patients were accrued to the optional pharmacology
study (15); thus, we cannot definitively state that response at this
dose is determined primarily by acetylator phenotype.
Patients who are fast acetylators paradoxically have slower
plasma clearance of amonafide and greater toxicity at a fixed dose
(17). This appears to be due to the inhibition of the oxidation
of amonafide (its major detoxification pathway) by N-acetyl-
amonafide, resulting in higher concentrations of both amonafide
and its active rnetabolite.4 From a clinical perspective, the dose of
amonafide used in this study may be too low for slow acetylators
(23), resulting in a decrease in both toxicity and response.
One way to deal with such variability in toxicity would be
to treat all patients at the same high dose (a dose high enough to
cause most patients to become severely neutropenic) and simul-
taneously to try to protect them with granulocyte-colony-stim-
ulating factors and an antibiotic. Whether such a strategy would
be safe remains to be demonstrated. A more rational and safer
strategy would be to dose patients initially according to their
acetylator status. This would ensure that most patients get a
biologically individualized and maximum dose. If necessary,
escalations could then be made in subsequent cycles by using
hematotoxicity as a criteria of adequate dosing. In the mean-
while, it should be noted that the maximum activity of
arnonafide has not been demonstrated in this study. The study
did not seek MTD for each patient, and the length of treatment
was limited by design to four cycles. What is shown is how
variable hematotoxicity is and how it is related to response.
Future studies should address the pharmacological principles of
initial dosing based on acetylator status. Such a study is now
under way (CALGB 9243).
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